What is ERAS's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 5.61B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for ERAS?

P/E (TTM) is n/a and 52-week range is $2.10 to $24.28 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s ERAS figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for ERAS?

The company profile lists net income (TTM) near $-327M, EPS (TTM) near $-0.95 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Erasca Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in San Diego, California, US, 342.2M shares outstanding, ISIN US29479A1088 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Erasca Inc

$ERAS

Health Care · Biotechnology

IR Run Scenarios

$16.03

+3.69%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Erasca, Inc. is a clinical stage precision oncology company. The company is headquartered in San Diego, California and currently employs 103 full-time employees. The company went IPO on 2021-07-15. The firm is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The firm has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.

Employees

103

Website

www.erasca.com/

IPO

2021-07-15

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)